Tau

News

Lilly's tau drug for Alzheimer's flunks phase 2 test

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug targ

News

Novo leads $100m financing for Alzheimer's player Asceneuron

Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.

News

Trial raises hopes for simple Alzheimer’s blood test

Testing a person’s blood for a protein called phosphorylated tau could provide a means of large-scale screening for Alzheimer’s disease (AD), according to a new study.

News

Roche ducks out of AC Immune Alzheimer's antibody alliance

After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibo

News

First data with subcutaneous Leqembi, and other CTAD news

Eisai and Biogen have reported data showing that a subcutaneous formulation of its Alzheimer’s disease therapy Leqembi matched the current intravenous version at clearing

Home

Sunbird, Glympse merge for earlier diagnosis of Alzheimer’s

Biotech Sunbird Bio has announced its completed merger with Glympse Bio, which it is hoped will accelerate development of the companies’ protein-based diagnostic technolog

Lilly's tau drug for Alzheimer's flunks phase 2 test

Novo leads $100m financing for Alzheimer's player Asceneuron

Trial raises hopes for simple Alzheimer’s blood test

Roche ducks out of AC Immune Alzheimer's antibody alliance

First data with subcutaneous Leqembi, and other CTAD news

Sunbird, Glympse merge for earlier diagnosis of Alzheimer’s

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Tau

Editor's Picks